Pea M, Bonetti F, Zamboni G, Martignoni G, Riva M, Colombari R, Mombello A, Bonzanini M, Scarpa A, Ghimenton C
Institute of Pathologic Anatomy, University of Verona, Italy.
Pathology. 1991 Jul;23(3):185-8. doi: 10.3109/00313029109063563.
HMB-45 (melanocytic cell-specific monoclonal antibody) immunoreactivity was investigated in 10 cases of angiomyolipoma (AML) (1 with massive regional lymph node involvement) of the kidney and detected in all of them. No HMB-45 immunoreactivity was found in other tumors of the region which can occasionally be confused with AML, such as renal cell carcinoma, Wilms' tumor, and retroperitoneal sarcoma (leiomyosarcoma and liposarcoma). These findings indicate that HMB-45 is not a melanocyte-restricted marker and suggest that its expression might be useful in distinguishing AML from other tumors of the kidney and retroperitoneum.
对10例肾血管平滑肌脂肪瘤（AML）（1例伴有大量区域淋巴结受累）进行了HMB - 45（黑素细胞特异性单克隆抗体）免疫反应性研究，结果在所有病例中均检测到HMB - 45免疫反应性。在该区域偶尔可能与AML混淆的其他肿瘤中未发现HMB - 45免疫反应性，如肾细胞癌、肾母细胞瘤和腹膜后肉瘤（平滑肌肉瘤和脂肪肉瘤）。这些发现表明HMB - 45不是黑素细胞限制性标志物，并提示其表达可能有助于将AML与肾脏和腹膜后的其他肿瘤区分开来。
